Annovis Bio Inc (ANVS)
8.10
-0.14
(-1.70%)
USD |
NYSE |
Sep 27, 16:00
8.14
+0.04
(+0.49%)
After-Hours: 20:00
Annovis Bio SG&A Expense (Annual): 6.244M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 6.244M |
December 31, 2022 | 8.996M |
December 31, 2021 | 6.058M |
December 31, 2020 | 3.586M |
Date | Value |
---|---|
December 31, 2019 | 0.8294M |
December 31, 2018 | 0.6023M |
December 31, 2017 | 0.4091M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
0.8294M
Minimum
2019
8.996M
Maximum
2022
5.143M
Average
6.058M
Median
2021
SG&A Expense (Annual) Benchmarks
Akero Therapeutics Inc | 31.07M |
Perspective Therapeutics Inc | 21.06M |
Electromed Inc | 34.49M |
Xtant Medical Holdings Inc | 64.29M |
Myomo Inc | 18.78M |